Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUVAL vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension (mild to moderate),Off-label: management of agitated states or psychiatric conditions (historically)
Hypertension
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
85-90% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.6-1.0 L/kg; indicates extensive extravascular distribution.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 60-70% due to first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, dose reduction by 50% is recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily.
Child-Pugh Class B or C: contraindicated; use not recommended.
Safety and efficacy not established in pediatric patients under 18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.,Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.,May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.,Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to rauwolfia serpentina or any component,Active peptic ulcer disease,Ulcerative colitis,History of mental depression, especially with suicidal tendencies,Electroconvulsive therapy (ECT) within 7 days
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No established dose adjustments; use is contraindicated in pregnancy due to known teratogenicity and fetotoxicity.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Rise slowly from sitting or lying down to prevent falls due to low blood pressure.,Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor.,Avoid alcohol, as it may worsen dizziness and drowsiness.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUVAL vs ALDORIL D30, answered by our medical review team.
RAUVAL is a Antihypertensive that works by Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUVAL and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUVAL is: 1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUVAL and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUVAL is classified as Category C. First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairme. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.